Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colistin Sulfate for Injection Post-marketing Prospective Study in Carbapenem-resistant Gram-negative Infections
CTR20222652Phase 4Completed
- Sponsor
- Shanghai Shyndec Pharmaceutical
- Start
- Oct 2022
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
A Phase 4 trial of colistin sulfate in Gram-negative bacterial infection, Acinetobacter baumannii infection, Pseudomonal infection, Klebsiella pneumoniae infection, urinary tract infection (UTI), sponsored by Shanghai Shyndec Pharmaceutical. Started Oct 2022; status: completed.
02
Drugs
colistin sulfate
03
Conditions
Gram-negative bacterial infectionAcinetobacter baumannii infectionPseudomonal infectionKlebsiella pneumoniae infectionurinary tract infection (UTI)
Beyond the preview
Go deeper on CTR20222652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222652.